Omeprazole promotes proximal duodenal mucosal bicarbonate secretion in humans

A Mertz-Nielsen, J Hillingsø, K Bukhave, J Rask-Madsen

Abstract
The proton pump inhibitor, omeprazole, surprisingly resulted in higher rates of proximal duodenal mucosal bicarbonate secretion than previously reported using an H₂ receptor antagonist for gastric acid inhibition. Gastroduodenal perfusions were performed in healthy volunteers to evaluate whether this incidental finding is explained by more potent gastric acid inhibition by omeprazole or might be caused by the different mode of drug action. Basal and stimulated gastric and duodenal bicarbonate secretion rates were measured in the same subjects in control experiments (n=17) and after pretreatment with high dose omeprazole (n=17) and ranitidine (n=9), respectively, by use of a technique permitting simultaneous measurements. Concentrations of bicarbonate were measured in the respective effluents by the method of back titration. Both omeprazole and ranitidine completely inhibited gastric acid secretion (pH 6.9 v 6.8; p>0.05). Omeprazole caused higher rates of basal (mean (SEM)) (597 (48) v 351 (39) μmol/h; p<0.02) and vagally stimulated (834 (72) v 474 (66) μmol/h; p<0.02), but not acid stimulated (3351 (678) v 2550 (456) μmol/h; p>0.05) duodenal bicarbonate secretion compared with control experiments. Also the combination of omeprazole and ranitidine increased (p=0.05) duodenal bicarbonate secretion, while ranitidine alone caused no change in either basal or stimulated secretion. In the stomach basal as well as vagally stimulated bicarbonate secretion was independent of the means of acid inhibition. These results show that the proton pump inhibitor, omeprazole, promotes proximal duodenal mucosal bicarbonate secretion apparently independent of its gastric acid inhibitory effect. The mechanism of action remains speculative.

(Gut 1996; 38: 6–10)

Keywords: bicarbonate secretion, duodenum, omeprazole, stomach, ranitidine.

Previous work has shown the existence of a pH gradient at the luminal surface of the gastroduodenal mucosa generated by active secretion of bicarbonate into the mucus gel layer.¹ ² As bicarbonate comprises the first line of defence against luminal acid and pepsin, recent research has focused on mucosal bicarbonate transport mechanisms both in experimental animals and in humans.³ The effect of various antilucer drugs on gastroduodenal bicarbonate secretion has been investigated in several studies,⁴ among which a few have concentrated on the effect of the proton pump inhibitor, omeprazole. Administration of omeprazole to cats has resulted in both reduced⁵ and increased⁶ rates of gastric bicarbonate secretion, while duodenal mucosal bicarbonate secretion in cats⁷ and in rats⁸ seems unaffected. Although relevant for clinical use in the treatment of acid related disorders, the potential effect of proton pump inhibitors on human gastroduodenal mucosal bicarbonate secretion has not previously been considered.

Incidentally, we observed that omeprazole resulted in higher rates of basal and vagally stimulated proximal duodenal mucosal bicarbonate secretion than previously reported using ranitidine as an inhibitor of gastric acid. To evaluate whether this finding might be explained by more potent inhibition of gastric acid by omeprazole or by the different mode of drug action, gastric and duodenal bicarbonate secretion rates were determined by use of a technique permitting simultaneous measurements.⁹ The same healthy volunteers were studied in control experiments without acid inhibition and after administration of omeprazole and ranitidine, respectively, using supramaximal, equipotent doses sufficiently large to obtain total inhibition of gastric acid secretion. In supplementary experiments, the combination of omeprazole and ranitidine on basal duodenal mucosal bicarbonate secretion was studied.

Methods
Healthy volunteers Twenty one healthy volunteers (12 men and nine women, median age 32 years, range 24–50), with no history of gastrointestinal or other medical diseases, consented to the study protocol. None of the healthy volunteers had ingested aspirin, non-steroidal anti-inflammatory drugs, or alcohol during the week before
entering the study, which was carried out according to the Helsinki II Declaration and approved by the ethics committee of Copenhagen and Frederiksborg.

Experimental design

Three series of experiments were performed. In the first series eight volunteers had simultaneous gastric and proximal duodenal perfusions twice (isotonic saline) with an interval of at least one week. The perfusions were performed in random order, that is, as one set of control perfusions (without acid suppression for determination of acid secretion in the stomach and bicarbonate secretion in the duodenum) and one set of experimental perfusions (for determination of bicarbonate secretion in the stomach and the duodenum) prior to which the subject was pretreated with a 60 mg oral dose of omeprazole (Astra A/S, Albertslund, Denmark) once daily for three days and 80 mg intravenously one hour before perfusion.

In the second series of experiments nine other volunteers had gastric and proximal duodenal perfusion three times. The perfusions were performed in random order and included one set of control perfusions (without acid suppression) and two sets of experimental perfusions prior to which the subject was pretreated with omeprazole as described above or with a 900 mg oral dose of ranitidine (Glaxo Denmark A/S, Brøndby, Denmark) 12 and two hours before the experiment and ranitidine 50 mg/h intravenously during perfusion.

Supramaximal doses of omeprazole and ranitidine were chosen to ensure the complete suppression of gastric acid secretion required for determination of gastric bicarbonate secretion. Each perfusion in the first and second series of experiments included a 60 minute equilibration period followed by a 30 minute basal period and a 60 minute sham feeding period. In the second series of experiments the duodenal bulb was acidified (HCl 0·1 M; 20 ml; 5 min) after the sham feeding period and then the duodenum was perfused for 45 minutes with isotonic saline. Attempts to measure gastric bicarbonate secretion after acidification of the stomach failed, because it was impossible to remove all the instilled acid within 30 minutes.

In the third series of experiments another four healthy volunteers had proximal duodenal perfusion once to study the effect of the combination of omeprazole and ranitidine. Each subject was pretreated with omeprazole as described above and after a 60 minute equilibration period the duodenum was perfused during basal conditions for 60 minutes. Then a 50 mg intravenous bolus injection of ranitidine was given. After a 30 minute equilibration period the duodenum was perfused for another 60 minutes during basal conditions. Ranitidine 50 mg/h was given intravenously during this final 90 minute period.

Simultaneous gastric and duodenal perfusions

After an overnight fast a six channel tube (16 French, outside diameter 5-3 mm, Pharmacia, Uppsala, Sweden) with three balloons was introduced orally. A Teflon coated guide wire was used for intubation (Amplatz Extra Stiff Wire Guide, outside diameter 0·9 mm, William Cook Europe, Bjaeverskov, Denmark) and the position of the tube was controlled by fluoroscopy. Proximal to a distal tungsten weight two button shaped inflatable latex balloons isolated a 3 cm long segment of the proximal duodenum. A pear shaped balloon in the distal stomach anchored the tube against the pylorus. The gastric balloon was inflated with 30 ml of air and the duodenal balloons with 5-15 ml of air. A double lumen gastric tube (16 French, AN 10 Anderson Samplers, Atlanta, GA, USA) was then placed in the distal antrum. The infusion port was located 8 cm proximal to the aspiration port. The isolated duodenal segment was perfused (Ivac 560 Pump, N C Nielsen, Glostrup, Denmark) with isotonic saline (2 ml/min; pH 7·0) using 51Cr]EDTA (10 μCi/ml) as a non-absorbable marker. Similarly, the stomach was perfused with isotonic saline containing phenol red (50 mg/l; pH 7·0), at a constant rate of 5 ml/min (LKB 2115 Multiperpx Pump, Bromma, Sweden). The effluents were collected from the stomach by intermittent suction (Pump AB, Einar Egnell, Trollhättan, Sweden) and from the duodenal segment by gravity drainage. During the perfusions saliva was continuously removed by dental suction. This has previously been shown to minimise the amount of swallowed saliva that could contribute to gastric bicarbonate content during basal conditions, but especially during modified sham feeding.

After the 60 minute equilibration period 15 minute gastric and duodenal samples were collected, except during modified sham feeding when gastric effluents were collected at five minute intervals. Modified sham feeding was performed using chewing gum (five pieces of fruit gum for 15 minutes). For acidification of the duodenal segment 20 ml of 100 mM HCl plus 54 mM NaCl were instilled into the segment for five minutes. In all subjects pH had returned to neutral values after 15 minutes when sampling was resumed.

Analytical procedures

Concentrations of hydrochloric acid in the gastric effluents from control experiments were determined by titration to pH=7·0 with 0·1 M NaOH (PHM82, Radiometer, Copenhagen, Denmark).

Concentrations of bicarbonate in 100 μl aliquots from gastric and duodenal effluents were determined in triplicate (Corning 965 Carbon Dioxide Analyzer, Corning Ltd, Halstead, England). Before analysis the samples were gassed with CO₂ free nitrogen for five minutes to remove dissolved carbon dioxide. The Corning analyser was calibrated daily against 2·5 and 5·0 mM NaHCO₃. The coefficients of variation were 12% (n=20) and 6% (n=20), respectively.

To determine the contamination of the
TABLE I Basal gastric and duodenal pH measurements in 17 healthy volunteers during control conditions and after administration of omeprazole and ranitidine; mean (SEM)

<table>
<thead>
<tr>
<th>Condition</th>
<th>Stomach pH</th>
<th>Duodenum pH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>2.32 (0.11)</td>
<td>7.40 (0.12)</td>
</tr>
<tr>
<td>Omeprazole</td>
<td>6.87 (0.08)</td>
<td>7.27 (0.06)</td>
</tr>
<tr>
<td>Ranitidine</td>
<td>6.92 (0.09)</td>
<td>7.33 (0.11)</td>
</tr>
</tbody>
</table>

duodenal test segment with pancreatic juice, trypsin was measured in the duodenal effluents as previously described.10

Activities of [51Cr] and concentrations of phenol red were determined both in gastric and duodenal effluents and served as markers for recovery and contamination of the respective test segment. Activities of [51Cr] were measured by gamma spectrometry (Model 1185, Searle Nuclear Chicago Division, Chicago, IL, USA). Concentrations of phenol red were measured spectrophotometrically at 560 nm after alkalinisation (pH = 11) by a 4:1 dilution with a 0·5 M Na3PO4 solution.

Calculations and statistical analyses

Rates of acid and bicarbonate secretion were calculated as the mean of the two or four 15 minute values obtained during the basal periods. Similarly, the results obtained after stimulation were calculated as the mean of the three five minute values obtained in the stomach and the first 15 minute value obtained in the duodenum after start of modified sham feeding and as the mean of all values obtained in the duodenum after luminal acidification.

The results were expressed as means (SEM). The bicarbonate data were analysed using repeated measures analysis of variance (RMANOVA) for a two way model. The normality assumption for this model was tested with the Kolmogorov-Smirnov statistics. The Levene’s statistic was used to test for equal variance.13 For most of the end points the normality assumption was violated. Thus, RMANOVA was performed on ranks. Student-Newman-Keul’s multiple comparison test was used for statistical analyses. Comparison of recoveries, contamination, and pH values were performed with Student’s t test for paired variables. All p values calculated were two tailed; the α value of significance was set at 0·05.

Results

Validation of methods

The mean recovery of the gastric and duodenal markers were 82 (2)% and 86 (2)%, respectively, with no differences between control, omeprazole, and ranitidine experiments. Values of basal and stimulated gastric and duodenal fluid outputs, in addition to recoveries of phenol red, [51Cr] and trypsin, showed no significant differences (p>0·3) between the groups. Only a small amount of gastric contents entered the duodenum (0·3 (0·1)%, that is 0·01 ml/min). The duodenogastric reflux equalled 0·8 (0·2)%, that is 0·06 ml/min. The contents of trypsin in the duodenal effluents were 0·6 (0·2)% of the average minimum trypsin output from the pancreas and a total of 11 samples from five subjects containing ≥25 μg/ml, 3% were excluded.

pH Measurements

Total inhibition of gastric acid secretion was achieved both after omeprazole and ranitidine administration and there was no significant difference between gastric pH values (p=0·8; Table I). The duodenal pH measurements showed no significant (p>0·7) differences between control, omeprazole and ranitidine experiments, respectively (Table I).

Gastric acid and bicarbonate secretion

In control experiments basal and vagally stimulated gastric acid secretion was 4·2 (1·1) mmol/h and 7·9 (1·7) mmol/h, respectively.

The basal rates of gastric bicarbonate secretion were 401 (56) μmol/h and 500 (104) μmol/h after ranitidine and omeprazole administration, respectively. The difference was not statistically significant (p>0·05; Table II). Modified sham feeding for 15 minutes caused a considerable rise (p<0·05) in bicarbonate secretion both in ranitidine, and in omeprazole experiments (Table II).

Proximal duodenal bicarbonate secretion

The basal rates of duodenal mucosal bicarbonate secretion in control and ranitidine experiments were 351 (39) μmol/h and 363 (63) μmol/h, respectively. In experiments with omeprazole the basal rate of proximal duodenal mucosal bicarbonate secretion was 597 (48) μmol/h (p<0·02) compared with control and ranitidine experiments, respectively (Table II and Figure).

Modified sham feeding for 15 minutes caused a moderate, but significant (p<0·05), rise in bicarbonate secretion in all experiments. The response to modified sham feeding after omeprazole administration was significantly

<table>
<thead>
<tr>
<th>Gastric HCO3- (μmol/l)</th>
<th>Duodenal HCO3- (μmol/l×3 cm)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Number</strong></td>
<td><strong>Basal</strong></td>
</tr>
<tr>
<td>Control</td>
<td>17</td>
</tr>
<tr>
<td>Ranitidine</td>
<td>9</td>
</tr>
<tr>
<td>Omeprazole</td>
<td>17</td>
</tr>
<tr>
<td>Ome + Ran</td>
<td>4</td>
</tr>
</tbody>
</table>

*p<0·05 compared with basal values; †p<0·02 compared with control and ranitidine (Student-Newman-Keul’s test); ‡p=0·05 compared with control (Student’s t test).
Omeprazole and duodenal bicarbonate

[p<0.02] higher than that seen in control and ranitidine experiments, respectively (Table II).

Luminal acidification of the duodenal bulb caused a considerable rise in bicarbonate secretion in all experiments. No significant differences in response were seen between control, omeprazole, and ranitidine experiments (Table II).

The basal rates of proximal duodenal bicarbonate secretion in the third series of experiments were 513 (93) μmol/h after omeprazole alone and 528 (78) μmol/h after the combination of omeprazole and ranitidine (p>0.05; Table II).

Discussion

The results of this study show that the proton pump inhibitor, omeprazole, promotes proximal duodenal mucosal bicarbonate secretion, but not gastric bicarbonate secretion, in healthy volunteers, apparently independent of its acid inhibitory effect. While basal and sham feeding stimulated transport rates of bicarbonate in the duodenum were significantly higher in omeprazole experiments than in control and ranitidine experiments, it cannot be excluded that a type II error occurred when testing the results obtained during luminal acidification caused by a large variation between subjects.

The basal rates of gastric bicarbonate secretion seen in ranitidine and omeprazole experiments were in the same order of magnitude as those previously reported by others.9 15 Similarly, the rates of basal and stimulated proximal duodenal mucosal bicarbonate secretion seen in control and ranitidine experiments were similar to those obtained by others using the same six-channel tube with three occluding balloons.12 16

The overall results of this study are, however, difficult to reconcile with much of the existing body of data relating to the action of omeprazole, considering that the compound is a highly specific, irreversible inhibitor of H⁺,K⁺ adenosine triphosphatase (ATPase), which blocks acid secretion in response to all modes of stimulation.17 H⁺,K⁺ ATPase inhibition has been reported to modulate ion transport in the small intestine of some amphibia,18 but this does not seem to occur in mammals.7 8 The mechanism responsible for the unexpected finding remains, therefore, obscure and theoretical considerations are speculative.

Nevertheless, omeprazole, compared with ranitidine, could inhibit acid secretion from heterotopic parietal cells in the duodenum with abnormal or lacking H₂ receptors and thus seem to stimulate bicarbonate secretion. This is compatible with the finding that the combination of omeprazole and ranitidine resulted in the same rates of proximal duodenal mucosal bicarbonate secretion as omeprazole alone.

Omeprazole might also act to increase bicarbonate secretion indirectly by influencing the distribution of bicarbonate in the tissue, the mucosal blood flow, motility, or local nerves, while a role of Helicobacter pylori is unlikely in this paired design study. The possibility that omeprazole modulates neural reflexes would explain the discrepancy between results obtained in anaesthetised animals5-8 and conscious humans.

The possibility that duodenal bicarbonate secretion is inhibited by ranitidine, rather than promoted by omeprazole, should also be considered. If that was the case, histamine H₂ receptor antagonists might be expected to decrease bicarbonate secretion both in the stomach and in the duodenum. Acid inhibition by supramaximal doses of ranitidine did not modulate gastric bicarbonate secretion, however, either in this study or in previous studies of healthy volunteers7 and duodenal mucosal bicarbonate secretion has been shown to be unaffected by ranitidine in animals.7 8 The apparent lack of effect of ranitidine could also be taken to imply that leakage of gastric acid occurred in control experiments despite the presence of occluding balloons. The rate of neutralised bicarbonate, however, as calculated from the appearance of the gastric marker in the duodenal effluents, did not exceed 20 μmol/h.

In conclusion, our results show that omeprazole promotes proximal duodenal mucosal bicarbonate secretion, but do not support the notion that histamine H₂ receptor blockade inhibits mucosal bicarbonate secretion. While the normal basal output of bicarbonate from the duodenum equals approximately 1000 μmol/h (duodenum about 9 cm; see Table II), or 25% of basal gastric acid secretion, the omeprazole-induced duodenal bicarbonate output amounts to approximately 1800 μmol/h, or 40% of basal gastric acid secretion, which could be neutralised by this alkali. Thus, the observed increase in duodenal neutralising capacity caused by omeprazole is likely to add to the well documented superiority of omeprazole (compared with histamine H₂ receptor antagonists) in duodenal ulcer healing.
Part of this work was presented at the Annual Meeting of
the American Gastroenterological Association in May 1994 in
New Orleans (Gastroenterology 1994; 106: A138) and was supported
by a research grant from Astra A/B Mölndal, Sweden. The
skilful technical assistance by Benedicte Bukhave is gratefully
acknowledged.

1 Takeuchi K, Magee D, Critchlow J, Matthews J, Silen W.
Studies of the pH gradient and thickness of frog gastric

2 Flemström G, Kiviläako E. Demonstration of a pH
gradient at the luminal surface of rat duodenum in vivo
and its dependence on mucosal alkaline secretion.

3 Flemström G. Gastric and duodenal mucosal secretion
of bicarbonate. In: Johnson LR, ed. Physiology of the
gastrointestinal tract. 3rd edition. New York: Raven Press,

4 Guslandi M. Effects of anti-ulcer drugs on gastrointestinal
bicarbonate secretion. Eur J Gastroenterol Hepatol 1990; 2:

5 Gutt K, Rask B, Gislason H, Fandriks L, Svanes K,
Gronbech JF. Gastric bicarbonate secretion, acid
secretion and mucosal blood flow during influence of
pentagastrin and omeprazole in the cat. Scand J

6 Fandriks L, Stage L. Simultaneous measurements of gastric
motility and acid-bicarbonate secretions in the anaes-

7 Fandriks L, Jonson C. Effects of acute administration of
omeprazole or ranitidine on basal and vagally stimulated
gastric acid secretion and alkalization of the duodenum
in anaesthetized cats. Acta Physiol Scand 1990; 138:
181–6.

8 Knutson L, Flemström G, Gustavsson S, Jedstedt G,
Lönnroth G. HCO3-secretion in rat duodenum after
treatment with omeprazole and ranitidine. Scand J

9 Odes HS, Hogan DL, Steinback JH, Balisteros MA, Koss
MA, Isenberg JJ. Measurement of gastric bicarbonate
secretion in the human stomach: different methods
produce discordant results. Scand J Gastroenterol 1992;

10 Mertz-Nielsen A, Hillingsø J, Eskerod O, Bukhave K,
Rask-Madsen J. Muscarinic M3 receptor inhibition
reduces gastroduodenal bicarbonate secretion and
promotes gastric prostaglandin E2 synthesis in healthy

Misoprostol inhibits gastric mucosal release of
endogenous prostaglandin E2 and thromboxane B2 in

12 Knutson L, Flemström G. Duodenal mucosal bicarbonate
secretion in man. Stimulation by acid and inhibition by
the alpha2-adrenoceptor agonist clonidine. Gut 1989; 30:
1705–15.

the scientist. Revision SSD 1.0. Kuo J, Fox E: Augsburg,

14 DiMagno EP. Alterations and consequences of inter-
digestive and poststimulatory human exocrine pancreatic
secretion in health and disease. In: Polsak JM, Bloom SR,
Wright NA, Butler AG, eds. Basic science in gastro-
enterology. Physiology of the gut. Ware, Herts, UK: Glaxo

15 Forsell H, Stenquist B, Olle L. Vagal stimulation of
human gastric bicarbonate secretion. Gastroenterology

16 Ainsworth MA, Keldsen J, Schaffalitzky de Muckadell OB.
Morphine inhibits secretion of bicarbonate from the human
duodenal mucosa. Scand J Gastroenterol 1990; 25:
1066–75.

17 McCravi D, Buckley MM-T, Heel RC. Omeprazole. An
updated review of its pharmacology and therapeutic use

18 White JF. Omeprazole inhibits H+ secretion by amphiemu

19 Noda LA, Roll TM, Bosma NB, Schwartz MP, Oosting J,
Rauws EA, et al. Gastric metaplasia and Helicobacter

20 Carrick J, Lee A, Hazzell S, Raitson M, Daskalopoulos G.
Campylobacter pylori, duodenal ulcer, and gastric
metaplasia: possible role of functional heterotopic tissue

21 Guslandi M. Alkali secretion by the human stomach: effect
Omeprazole promotes proximal duodenal mucosal bicarbonate secretion in humans.

A Mertz-Nielsen, J Hillingsø, K Bukhave and J Rask-Madsen

Gut 1996 38: 6-10
doi: 10.1136/gut.38.1.6

Updated information and services can be found at:
http://gut.bmj.com/content/38/1/6

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections
Stomach and duodenum (1689)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/